2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Rating of “Hold” from Analysts

Shares of 2seventy bio, Inc. (NASDAQ:TSVT) have earned an average rating of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $13.17.

Several analysts have weighed in on TSVT shares. Citigroup boosted their price objective on 2seventy bio from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Leerink Partnrs raised 2seventy bio from a “market perform” rating to an “outperform” rating in a research note on Wednesday, January 31st. Wedbush restated a “neutral” rating and set a $5.00 target price on shares of 2seventy bio in a report on Monday, March 18th. TD Cowen reaffirmed a “market perform” rating on shares of 2seventy bio in a research note on Wednesday, January 31st. Finally, SVB Leerink raised shares of 2seventy bio from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $5.00 to $18.00 in a research note on Wednesday, January 31st.

2seventy bio Stock Performance

Shares of TSVT opened at $4.76 on Monday. The stock has a fifty day moving average price of $4.95 and a two-hundred day moving average price of $4.04. 2seventy bio has a 52-week low of $1.53 and a 52-week high of $12.69. The company has a market cap of $244.66 million, a price-to-earnings ratio of -1.08 and a beta of 1.87.

2seventy bio (NASDAQ:TSVT) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.11. 2seventy bio had a negative return on equity of 59.19% and a negative net margin of 216.73%. The firm had revenue of $10.68 million during the quarter, compared to the consensus estimate of $13.91 million. During the same quarter in the previous year, the company posted ($0.60) EPS. As a group, research analysts predict that 2seventy bio will post -1.39 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Casdin Capital, Llc purchased 330,000 shares of the business’s stock in a transaction on Monday, March 25th. The shares were purchased at an average price of $5.07 per share, with a total value of $1,673,100.00. Following the completion of the purchase, the director now owns 1,960,000 shares in the company, valued at approximately $9,937,200. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 2.60% of the stock is owned by company insiders.

Institutional Trading of 2seventy bio

Several hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of 2seventy bio by 15.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,629 shares of the company’s stock valued at $62,000 after purchasing an additional 1,925 shares during the period. Deutsche Bank AG increased its position in shares of 2seventy bio by 15.7% in the third quarter. Deutsche Bank AG now owns 26,134 shares of the company’s stock valued at $102,000 after acquiring an additional 3,537 shares during the last quarter. SG Americas Securities LLC increased its position in shares of 2seventy bio by 20.9% in the fourth quarter. SG Americas Securities LLC now owns 27,315 shares of the company’s stock valued at $117,000 after acquiring an additional 4,715 shares during the last quarter. Exchange Traded Concepts LLC increased its position in 2seventy bio by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 34,616 shares of the company’s stock worth $148,000 after buying an additional 8,778 shares during the last quarter. Finally, Brighton Jones LLC acquired a new position in 2seventy bio during the third quarter worth approximately $60,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.